Short answer
Candel Therapeutics, Inc. (CADL) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results announced March 12, 2026: details in Exhibit 99.1.
Candel Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results announced March 12, 2026: details in Exhibit 99.1
- Filing "furnished" not "filed," meaning results carry no Section 18 liability: standard for earnings releases
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Candel Therapeutics, Inc. 8-K filings
Get the next CADL 8-K as it lands
Follow CADL for push alerts, or ask the research agent what this filing means.